Today: 4 June 2026
Upstart Holdings (UPST) Stock Jumps After CEO’s $1.38 Million Buy — Why It Matters Now
15 May 2026
2 mins read

Upstart Holdings (UPST) Stock Jumps After CEO’s $1.38 Million Buy — Why It Matters Now

NEW YORK, May 15, 2026, 05:04 EDT

  • Upstart jumped 10.1% Thursday after CEO Paul Gu picked up 50,000 shares, according to a filing.
  • The deal comes on the heels of a first quarter that saw loan volumes accelerate even as margins slipped.
  • With slim chances for a rate cut, funding costs stay elevated and borrower demand remains closely watched.

Upstart Holdings got a jolt Thursday after a fresh regulatory filing revealed CEO Paul Gu scooped up 50,000 shares, spending $1.375 million on the buy. Gu made the May 13 purchase at $27.50 per share via The Gu Qiao Family Trust, where he serves as managing member, according to a Form 4. That’s the SEC’s standard insider trading disclosure.

Shares of the San Mateo, California-based company jumped 10.1% to finish at $29.71 on May 14. Investors are weighing a return to loan volume growth, but there’s lingering uncertainty around margins and the expense of funding loans in a market still marked by high rates.

Timing’s key here: Gu stepped in as CEO on May 1, taking over from co-founder Dave Girouard, now executive chairman, after a planned leadership change. In these early days at the helm, Gu’s pushing to prove Upstart’s lending marketplace can keep growing—and keep profitability in the mix.

Upstart claims its artificial intelligence tools help banks and credit unions underwrite a range of consumer loans—personal, auto, home-equity lines of credit, and small-dollar offerings among them. For the first quarter, the company logged 425,356 loans originated, a jump of 77% from a year ago. Total originations hit about $3.4 billion, up 61%. Revenue climbed 44% to $308 million.

Profit numbers told a tougher story. Upstart posted a net loss of $6.6 million, deeper than the $2.4 million loss a year ago. Adjusted EBITDA slipped to $40.5 million, down from $42.6 million, and the margin on that metric narrowed to 13%, a drop from 20%.

“Originations jumped 61% in Q1; revenue climbed 44% from a year earlier — both figures lining up well with our full-year targets,” Gu said in the earnings release. “Starting out as CEO, my priorities are clear: create a high-growth, capital-efficient company that can produce solid long-term returns.” SEC

This week, the company picked up fresh distribution. USF Credit Union—a Tampa cooperative holding more than $1.4 billion in assets and serving upwards of 80,000 members—announced May 13 it’s teaming up with Upstart to roll out personal loans. “Expand access to credit using AI-powered technology,” said Richard Sellwood, senior vice president and chief operating officer at USF CU, on the partnership. Ed Walters, Upstart’s vice president of lending partnerships, added that USF Credit Union can now tap a broader pool of potential members through a digital lending platform. Upstart Network, Inc.

Consumer-finance stocks are seeing mixed signals. SoFi posted a record $12.2 billion in first-quarter originations and described U.S. borrowers as resilient, yet the stock slipped after it stuck with its 2026 forecast. LendingClub, now rebranding as Happen Bank, logged $2.7 billion in originations—up 31%. These figures suggest healthy loan appetite, but they also set a higher bar for Upstart’s performance.

Rates remain tricky. On Polymarket, traders are pricing in a 98% probability the Fed holds steady in June, and a 72% chance there won’t be any cuts in 2026. Over on Kalshi’s 2026 rate-cut market, the “exactly 0 cuts” contract hovers around 69%. Higher rates, of course, mean pricier personal loans for borrowers and steeper yields expected by loan buyers. Polymarket

The risk side isn’t buried. In its most recent quarterly filing, Upstart flagged several pressure points: softening macro conditions could hit borrower demand, slow loan funding from both lending partners and institutional buyers, push up funding costs, and force heavier use of its own balance sheet. The company also pointed to the possibility that institutional capital might dry up or no longer be available on acceptable terms. If investor appetite for loans facilitated by Upstart keeps falling, there’s a clear threat to performance.

Next week brings another chance for investors to hear directly from management. Upstart’s Gu is set to appear at the J.P. Morgan Global Technology, Media & Communications Conference, taking the stage May 19 at 1:15 p.m. Pacific.

Stock Market Today

  • Parabilis Medicines Targets $413M IPO to Propel Desmoid Tumor Drug into Phase 3
    June 4, 2026, 10:07 AM EDT. Massachusetts biotech Parabilis Medicines plans an IPO on Nasdaq, aiming to raise up to $476 million to fund the phase 3 trial of zolucatetide, a drug for rare noncancerous desmoid tumors. The offering includes 25 million shares priced between $17 and $19 each, potentially netting $413.6 million. Additional funds come from Regeneron's $50 million upfront payment and $75 million equity investment. Parabilis will allocate $150 million for desmoid tumor development and $120 million for phase 1 trials in other Wnt pathway-related cancers and conditions. The company is led by CEO Mathai Mammen, ex-J&J R&D head, with a focus on advancing helicon peptides designed to bind challenging flat surfaces. Prior fundraising rounds raised over $700 million, highlighting strong investor support ahead of the IPO.

Latest articles

Ciena Corporation Stock Faces $416 Reality Check as AI Network Push Heads to Brazil

Ciena shares fall after strong results, AI trade takes a hit

4 June 2026
Ciena shares plunged 9.5% premarket to $561.51 despite beating Q2 revenue and profit estimates and raising full-year guidance, as investors—already pricing in an AI-driven boom—found the outlook insufficient; two customers made up 34% of revenue, highlighting risk from concentrated orders and volatile AI-linked demand.
Splash Beverage Stock Climbs — NYSE Details for Traders

Splash Beverage Stock Climbs — NYSE Details for Traders

4 June 2026
Splash Beverage soared 71% to $0.2420 after filing a plan to regain NYSE American compliance, with shares quoted at $0.3650 premarket as investors react to survival efforts amid expired Medterra CBD talks, a sharp revenue drop to $4,224, a $2.14 million loss, and just $381,195 in cash, leaving the company dependent on new deals and financing to avoid delisting.
Intel Shares Drop Even as Tech Climbs—AI Trade Not Enough

Intel Shares Dip Premarket Despite Foxconn AI Deal

4 June 2026
Intel shares slid 3.71% to $108.53 premarket as a new AI partnership with Foxconn failed to offset a chip-sector selloff sparked by Broadcom’s disappointing results; investors face uncertainty as Intel and Foxconn gave no financial details, customer names, or launch timeline for their AI collaboration, raising questions about how soon the deal could boost revenue.
Archer Aviation stock moves up as investors watch for 2026 air-taxi test

Archer Aviation Drops Pre-Market With Cash Burn In Focus

4 June 2026
Archer Aviation shares slid 3.3% pre-market to $6.53 as investors weighed heavy quarterly losses and rising cash needs for certification, testing, and manufacturing, despite progress on FAA milestones; the company warned it may need more capital on poor terms if costs rise or development delays, leaving the stock exposed to regulatory and financial risks.
Nvidia Faces New AI Test After Broadcom Drop Hits Chip Stocks

Nvidia Faces New AI Test After Broadcom Drop Hits Chip Stocks

4 June 2026
Nvidia shares slipped to $214.75 premarket as a Broadcom-led chip selloff rattled AI stocks, after Broadcom’s disappointing AI chip results and flat 2027 revenue target triggered a $315 billion market value drop; investors are questioning whether Nvidia’s rapid growth and dominance can keep matching sky-high expectations despite record Q1 revenue and expanded buybacks.
Redwire Stock Jumps 22% as Drone Showcase Draws Attention to Record Backlog
Previous Story

Redwire Stock Jumps 22% as Drone Showcase Draws Attention to Record Backlog

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus
Next Story

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

Go toTop